Streetbeat News

GRCL

Gracell Biotechnologies Inc

Employees

Industry

Pharmaceutical Preparation Manufacturing

gracell biotechnologies inc. is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. leveraging its pioneering fastcar and truucar technology platforms, gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional car-t therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective car-t therapies for solid tumors.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

U.S. stocks traded higher with the Dow Jones gaining over 100 points. Energy shares led the gains, while health care shares fell slightly. The S&P CoreLogic Case-Shiller 20-city home price index reported a 4.9% increase year-over-year in October. Gracell Biotechnologies surged 59% after AstraZeneca agreed to acquire it. Inspira Technologies rose 93% on positive blood sensor results. Stratasys gained 11% after a buyout proposal from Nano Dimension. Adit EdTech announced plans to de-list from NYSE American, causing its shares to drop 18%. Milestone Pharmaceuticals fell 34% after an FDA refusal to file letter. Oncternal Therapeutics dropped 12% after updating its Phase 1/2 study status.

Portfolio Pulse from Avi Kapoor

December 26, 2023 | 5:20 pm

BTIG analyst Justin Zelin has downgraded Gracell Biotechnologies (NASDAQ:GRCL) from Buy to Neutral, indicating a shift in the firm's outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 26, 2023 | 5:17 pm

HC Wainwright & Co. analyst Emily Bodnar has downgraded Gracell Biotechnologies (GRCL) from Buy to Neutral and reduced the price target from $13 to $10.

Portfolio Pulse from Benzinga Newsdesk

December 26, 2023 | 3:29 pm

Gracell Biotechnologies has agreed to be acquired by AstraZeneca for about $1.2 billion, causing GRCL shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

December 26, 2023 | 1:23 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. RayzeBio (RYZB) saw a dramatic increase of 98.2%, while Gracell Biotechnologies (GRCL) and 60 Degrees (SXTP) also posted substantial gains. Conversely, Milestone Pharmaceuticals (MIST) and other stocks such as SINTX Techs (SINT) and Panbela Therapeutics (PBLA) faced notable declines. These movements reflect changes in investor sentiment and market dynamics affecting these companies' valuations.

Portfolio Pulse from Benzinga Insights

December 26, 2023 | 1:07 pm

Sentage Holdings Inc. (SNTG) shares dropped by 5.1% in pre-market trading after reporting a loss of 46 cents per share for the six months ended June 30, 2023, compared to a loss of 41 cents per share in the previous year. The company's total operating revenue was $82, down from $0.18 million year-over-year. Other stocks experienced pre-market movements, with notable gainers including Volcon, Inc. (VLCN), Gracell Biotechnologies Inc. (GRCL), and AERWINS Technologies Inc. (AWIN), and significant losers such as NextPlay Technologies, Inc. (NXTP), Prospector Capital Corp. (LDTC), and Vroom, Inc. (VRM).

Portfolio Pulse from Avi Kapoor

December 26, 2023 | 1:01 pm

AstraZeneca Plc (NASDAQ:AZN) is set to acquire Gracell Biotechnologies Inc (NASDAQ:GRCL) to enhance its cell therapy portfolio. The deal is valued at $2.00/share plus a contingent value right of $0.30/share, totaling approximately $1.2 billion if all conditions are met. The acquisition includes GC012F, a CAR-T therapy for multiple myeloma and other diseases. Gracell's shares surged 63.3% in premarket trading after the announcement.

Portfolio Pulse from Vandana Singh

December 26, 2023 | 11:47 am

In Tuesday's pre-market session, several stocks are moving higher following various positive developments. Gracell Biotechnologies Inc. (GRCL) saw a significant pre-market increase after AstraZeneca announced plans to acquire the company for up to $1.2 billion. Other stocks experiencing gains include Manchester United plc (MANU) after Jim Ratcliffe's minority stake purchase, Stratasys Ltd. (SSYS) following a preliminary acquisition proposal from Nano Dimension, and Hollysys Automation Technologies Ltd. (HOLI) after a raised all-cash offer from Dazheng Group. Additionally, Li Auto Inc. (LI), Helmerich & Payne, Inc. (HP), Altimmune, Inc. (ALT), SES AI Corporation (SES), and Canadian Solar Inc. (CSIQ) also recorded pre-market gains.

Portfolio Pulse from Avi Kapoor

December 26, 2023 | 11:05 am

AstraZeneca has agreed to acquire Gracell Biotechnologies for approximately $1 billion in cash, with an additional contingent value right of $0.30 per share upon reaching a regulatory milestone, potentially increasing the total value to $1.2 billion. The offer represents a significant premium over Gracell's recent market prices. The acquisition aims to bolster AstraZeneca's cell therapy capabilities in oncology and autoimmune diseases. The deal is expected to close in Q1 2024, pending regulatory and shareholder approvals, and does not affect AstraZeneca's 2023 financial guidance.

Portfolio Pulse from Benzinga Newsdesk

December 26, 2023 | 7:09 am

In Tuesday's after-market session, several healthcare stocks experienced significant movements. Reshape Lifesciences (RSLS) saw a 58.2% increase, while NightHawk Biosciences (NHWK) rose by 12.9%. Minerva Surgical (UTRS) increased by 9.99%, Yield10 Bioscience (YTEN) by 9.5%, Inhibikase Therapeutics (IKT) by 8.33%, and Senti Biosciences (SNTI) by 8.31%. Conversely, LumiraDx (LMDX) fell by 7.7%, Fate Therapeutics (FATE) by 6.67%, Sera Prognostics (SERA) by 5.51%, Gracell Biotechnologies (GRCL) by 5.0%, First Wave BioPharma (FWBI) by 4.84%, and Hepion Pharmaceuticals (HEPA) by 4.82%.

Portfolio Pulse from Benzinga Insights

December 12, 2023 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.